Showing 1561-1570 of 7113 results for "".
COVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Juvederm Approved for Lips, CoolMini Applicator Cleared
https://practicaldermatology.com/topics/psoriasis/juvederm-approved-for-lips-coolmini-applicator-cleared/18828/In this edition, a look at Allergan's Juvederm Voluma XC approval for lips an Zeltiq's CoolMini applicator for treatment of the sub mental area. Plus, there's new data for secukinumab in psoriatic arthritis (PSA) and Kathleen Sebelius has joined the Board of Directors of Dermira.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Merkel Cell Carcinoma Update
https://practicaldermatology.com/topics/skin-cancer-photoprotection/merkel-cell-carcinoma-update/20217/News that “Margaritaville” singer Jimmy Buffett died from Merkel cell carcinoma is shining a spotlight on this rare and aggressive form of skin cancer. Leonel Hernandez Aya, MD, a medical oncologist specializing in skin cancers at the Sylvester Comprehensive Cancer Center at the University of MiamiPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 3
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-3/32759/Host Neal Bhatia, MD, FAAD, and guests Jason E. Hawkes, MD, MS, FAAD, and Laura K. Ferris, MD, PhD, FAAD, discuss the importance of patients acting at the first sign of flare with generalized pustular psoriasis, and the risks of serious illness and mortality.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 4
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-4/32760/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss updated guidelines for generalized pustular psoriasis treatment and evaluation in light of the current understanding of the IL-36 pathway, as well as the mechanism of action of spesolimaVitiligo Uncovered: Exploring the Latest Advances in Treatment and Care
https://practicaldermatology.com/youngmd-connect/ymdc-workshops/vitiligo-uncovered-exploring-latest-advances-treatment-and-care/29519/In this on-demand webinar, Dr. Domingues and Dr. Silverberg provide a comprehensive overview of vitiligo. This session covers the various types of vitiligo, essential patient evaluation techniques, and understanding disease progression. Learn about treatment strategies from both private practice andStrategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.